Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsSílvia Soares, Augusto Nogueira, Ana Coelho, Joana Assis, Deolinda Pereira, Isabel Bravo, Rui Medeiros
Several studies have suggested that there are single nucleotide polymorphisms (SNPs) that can be considered potential biomarkers in the prognosis and therapeutic response of cancer patients. The present study investigated the association between
This hospital-based retrospective cohort study included 260 patients with cervical cancer, FIGO stages Ib2-IVa, who underwent CRT (cisplatin). Genetic polymorphisms analysis was performed by allelic discrimination with real-time polymerase chain reaction (RT-PCR).
Our results indicated a link between
This is the first study evaluating the relationship between these polymorphisms and clinical toxicities in cervical cancer patients submitted to CRT with cisplatin. These results may contribute toward a better understanding of the influence of genetic polymorphisms in genes associated with DNA repair in the clinical response to CRT of patients with cervical cancer.
- • Accepted on 10/05/2017
- • Available online on 08/07/2017
This article is available as full text PDF.
- Soares, Sílvia [PubMed] [Google Scholar] 1
- Nogueira, Augusto [PubMed] [Google Scholar] 1, 2, 3
- Coelho, Ana [PubMed] [Google Scholar] 1
- Assis, Joana [PubMed] [Google Scholar] 1, 2
- Pereira, Deolinda [PubMed] [Google Scholar] 1, 4
- Bravo, Isabel [PubMed] [Google Scholar] 5
- Medeiros, Rui [PubMed] [Google Scholar] 1, 3, 6, * Corresponding Author (firstname.lastname@example.org)
Molecular Oncology and Viral Pathology Group – Research Center, Portuguese Institute of Oncology, Porto - Portugal
FMUP, Faculty of Medicine of Porto University, Porto - Portugal
Research Department, Portuguese League Against Cancer (NRNorte), Porto - Portugal
Oncology Department, Portuguese Institute of Oncology, Porto - Portugal
Medical Physics, Radiobiology and Radioprotection Group – Research Center, Portuguese Institute of Oncology, Porto - Portugal
CEBIMED, Faculty of Health Sciences of Fernando Pessoa University, Porto - Portugal
Sílvia Soares and Augusto Nogueira have contributed equally to this work.